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aStatins and All-Cause Mortality in High-Risk Primary Prevention: A
Meta-analysis of 11 Randomized Controlled Trials Involving 65,229
Participants
Ray KK, Kondapally SR, Erqou SE, et al. Arch Intern Med 2010;170:
1024-31.
Conclusion: There is no benefit of statin therapy on all-cause mortality
in a high-risk primary prevention setting.
Summary: The Justification for the Use of Statins in Prevention
Intervention Trial Evaluating Rosuvastatin (JUPITER) reported that pa-
tients with comparatively low levels of low-density lipoprotein (LDL) cho-
lesterol (130 mg/dL) and baseline levels of high-sensitivity C-reactive
protein (HS-CRP; 2 mg/L) reduced all-cause mortality by 20% (Ridker
PM, N Eng J Med 2008;359:2195-207). However, the JUPITER findings
have been questioned as occurring by chance or as being an exaggerated
observation (Yusuf S, Lancet 2009;373:1152-5). The authors undertook a
new metaanalysis of published clinical trials (including information previ-
ously unpublished by such studies) to assess whether statins reduce all-cause
mortality in the setting of high-risk primary prevention populations. The
goal was to determine if statin therapy reduces all-cause mortality in inter-
mediate- to high-risk individuals without a history of cardiovascular disease.
The authors identified trials for the analysis through computerized
literature searches of MEDLINE and Cochrane databases from January
1970 to May 2009. Trials had to be prospective, randomized, and con-
trolled, evaluating statin therapy in individuals free from cardiovascular
disease at baseline. Data were extracted for the number of patients random-
ized and for mean duration of follow-up. The number of incident deaths was
obtained though the principle publication or by correspondence with inves-
tigators. For the analysis, 11 studies were identified and data combined from
the studies, with the sample effects pooled using a random-effects model
analysis with heterogeneity assessed with the I2 statistic.
Data were available on 65,229 participants followed-up for approxi-
mately 244,000 person-years, during which 2793 deaths occurred. Use of
statins in this high-risk primary prevention setting was not associated with a
statistically significant reduction (RR, 0.91; 95% CI, 0.83-1.01) in all-cause
mortality. There was no statistical evidence of heterogeneity among studies
(I2  23%; 95% CI, 0%-61%; P  .23).
Comment: Three-quarters of patients who take statins take them for
primary prevention. Depending on perspective, their study has enormous
implications for expenditures (from payers perspective) or revenue (from
industry perspective). An editorial by Dr Lee A. Green in the same issue of
Archives of Internal Medicine (2010;170:1007-8), points out this advocates
for lipid-lowering therapy for primary prevention feel benefit would likely
accrue over a longer time of observation. Skeptics postulate little incremental
benefit will accrue later. Accompanying the Ray et al meta-analysis is another
article in the same issue of Archives of Internal Medicine by de Lorgeril et al,
“Cholesterol Lowering, Cardiovascular Diseases, and the Rosuvastatin-
JUPITER Controversy, A Critical Reappraisal” (2010;170:1032-6), in
which the authors point out that the JUPITER trial is the only trial that has
shown benefit for primary prevention with statins. These authors are highly
critical of the JUPITER trial in terms of industry control, industry-
performed statistical analysis, conflicts of interest of the authors, and prema-
ture ending of the trial. It may be that statins for primary prevention of
cardiovascular disease in patients at risk is not the “home run” everyone
believes it is. When used for primary prevention, the only beneficiaries of
statin therapy may be the pharmaceutical industry and their stockholders!
Contemporary Results for Carotid Endarterectomy for Asymptomatic
Carotid Stenosis
Woo K, Garg J, Hye RJ, et al. Stroke 2010;41:975-9.
Conclusion: Stroke rates with carotid endarterectomy (CEA) and best
medical management for asymptomatic carotid stenosis are similar.
Summary:Overall, 40% to 60% of CEAs are performed for asymptom-
atic carotid stenosis. Statins may reduce risk of stroke by up to 50% (Ridker
PM et al, N Engl J Med 2008;359:2195-207; and Stroke Prevention by
Aggressive Reduction in Cholesterol Levels [SPARCL] Investigators,
N Engl J Med 2006;355:549-59) in patients with asymptomatic carotid
stenosis. Therefore, current best medical management of asymptomatic
patients with significant carotid stenosis includes use of statins as well as
antiplatelet therapy, smoking cessation, and control of hypertension. The
authors sought to compare modern results of CEA for asymptomatic carotid
stenosis with previously published stroke rates for best medical management
of patients with asymptomatic carotid stenosis. A secondary purpose was to
w
c
878stablish patient factors that may result in increased risk of post-CEA
orbidity and mortality.
Patients who underwent CEA for asymptomatic carotid stenosis from
005, 2006, and 2007 were identified through the National Surgical Qual-
ty Improvement Program (NSQIP) database. Preoperative and postopera-
ive variables were analyzed, including 30-day stroke, death, and myocardial
nfarction. The authors identified 10,423 CEAs, of which 5009 were for
symptomatic carotid stenosis. Stroke, death, andmyocardial infarction rates
n the patients treated with CEA for asymptomatic carotid stenosis were
.9%, 0.56%, and 0.22%, respectively. The authors then reasoned that if the
.96% perioperative stroke rate from the contemporary NSQIP analysis was
ombined with the 5-year stroke risk after CEA of 3.8% from the Asymp-
omatic Carotid Surgery Trial (ACST), that the annual average stroke rate
ould be 1% and that this number is comparable to a stroke rate of 0.8% for
est medical management from the Second Manifestations of Arterial Dis-
ase Study Trial (Goessens BMB et al, Stroke 2007;38:1470-5). Multivari-
ble analysis showed chronic obstructive pulmonary disease, congestive
eart failure, and myocardial infarction 6 months preoperatively were all
ssociated with an increased risk of adverse events after CEA for asymptom-
tic carotid stenosis.
Comment: This study was published before the recent 10-year update
f ACST (Halliday A et al, Lancet 2010;376:1074-84). Given the recent
CST findings, the comparison of NISQIP data in this report with Smart
rial data loses some of its luster. The results of the ACST trial probably
hould be taken more seriously in terms of evaluating the efficacy of CEA for
symptomatic patients with carotid stenosis. The value of the Woo et al
eport lies in the documentation of the stroke and death and myocardial
nfarction rates in the NSQIP database. More and more data indicate
urgeons have become quite good at performing CEA in asymptomatic
atients. However, it is also becoming increasingly evident that despite the
bility of surgeons to safely perform CEA in the asymptomatic patient, the
peration likely has minimal overall benefit from a public health perspective.
mportance of Refractory Pain and Hypertension in Acute Type B
ortic Dissection: Insights From the International Registry of Acute
ortic Dissection (IRAD)
rimarchi S, Eagle KA, Nienaber CA, and the IRAD Investigators. Circu-
ation 2010;122:1283-9.
Conclusion: In acute type B aortic dissection, refractory hypertension
nd recurrent pain are associated with increased in-hospital mortality espe-
ially when managed medically.
Summary: In patients with acute type B dissection, refractory or
ecurrent pain, or refractory hypertension may indicate pending rupture or
xtending dissection and therefore a more adverse prognosis. The authors
sed patients in the International Registry of Acute Aortic Dissection
IRAD) to investigate the impact of refractory hypertension and/or refrac-
ory pain on outcomes of acute type B aortic dissection. They compared 69
atients with refractory or recurrent pain or refractory hypertension (group
) with 296 patients without clinical complications at presentation (group
I). They excluded patients with high risk or classic complications of dissec-
ion from analysis. Overall in-hospital mortality was 6.5%. Mortality was
7.4% in group I vs 4.0% in group II (P  .0003). With medical manage-
ent, mortality in group I was significantly increased at 35.6% compared
ith 1.5% in group II (P  .0003). Mortality rates after surgical (20% vs
8%; P .74) or endovascular management (3.7% vs 9.1%; P .5) were not
ifferent between group I and group II, respectively. By multivariable
ogistic regression analysis, refractory or recurrent pain or refractory hyper-
ension were predictors of in-hospital mortality (odds ratio, 3.31; 95% CI,
.04-10.45; P  .041).
Comment: The data indicate that in patients with uncomplicated type
acute aortic dissection, medical therapy has an excellent short-term
utcome. In-hospital mortality, however, is increased in patients with acute
ype B aortic dissection who have recurrent and/or refractory pain or
efractory hypertension and are managed with medical management alone.
hese patients have outcomes worse than those with no complications of
heir type B aortic dissection, but their natural history appears to be better
han patients who havemore adverse complications of aortic dissection, such
s limb ischemia or organmalperfusion. Given themortality risk of the group
ith recurrent and/or refractory pain or refractory hypertension endovas-
ular management, when possible, seems appropriate.
